Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives

References

• Tritton T, Bennett B, Brohan E, et al. Health utilities and quality of life in individuals with tuberous sclerosis complex (TSC) who experience epileptic seizures: a web-based survey. Epilepsy Behav. 2019;92:213–220. doi:10.1016/j.yebeh.2018.11.02130690322
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817–824. doi:10.1016/S0140-6736(12)61767-X23312829
   PubMed Web of Science ®Google Scholar
• Franz DN, Agricola K, Mays MA, et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015;78(6):929–938. doi:10.1002/ana.2452326381530
   PubMed Web of Science ®Google Scholar
• Abs E, Goorden SM, Schreiber J, et al. TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice. Ann Neurol. 2013;74(4):569–579. doi:10.1002/ana.2394323720219
   PubMed Web of Science ®Google Scholar
• Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008;63(4):444–453. doi:10.1002/ana.2133118389497
   PubMed Web of Science ®Google Scholar
• Overwater IE, Rietman AB, Bindels-de Heus K, et al. Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial. Neurology. 2016;87(10):1011–1018. doi:10.1212/WNL.000000000000307727511181
   PubMedGoogle Scholar
• Li M, Zhou Y, Chen C, et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019;14(1):39. doi:10.1186/s13023-019-1012-x30760308
   PubMed Web of Science ®Google Scholar
• French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153–2163. doi:10.1016/S0140-6736(16)31419-227613521
   PubMed Web of Science ®Google Scholar
• Franz DN, Lawson JA, Yapici Z, et al. Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures. Epilepsia. 2018;59(6):1188–1197. doi:10.1111/epi.1408529727013
   PubMed Web of Science ®Google Scholar
• Curatolo P, Nabbout R, Lagae L, et al. Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol. 2018;22(5):738–748. doi:10.1016/j.ejpn.2018.05.00629880258
   PubMed Web of Science ®Google Scholar
• Curatolo P, Jóźwiak SNabbout R. TSC consensus meeting forSEGA and epilepsy management. management of epilepsy associated with tuberous sclerosis complex (TSC): clinicalrecommendations. Eur J Paediatr Neurol. 2012;16(6): doi:10.1016/j.ejpn.2012.05.004
   Google Scholar
• Franz DN, Lawson JA, Yapici Z, et al. Everolimus for treatment-refractory seizures in TSC: extension of a randomized controlled trial. Neurol Clin Pract. 2018;8(5):412–420. doi:10.1212/CPJ.000000000000051430564495
   PubMedGoogle Scholar
• Cox RL, Calderon de Anda F, Mangoubi T, Yoshii A. Multiple critical periods for rapamycin treatment to correct structural defects in Tsc-1-suppressed brain. Front Mol Neurosci. 2018;11:409. doi:10.3389/fnmol.2018.0040930467464
   PubMed Web of Science ®Google Scholar
• Peters JM, Prohl A, Kapur K, et al. Longitudinal effects of everolimus on white matter diffusion in tuberous sclerosis complex. Pediatr Neurol. 2019;90:24–30. doi:10.1016/j.pediatrneurol.2018.10.00530424962
   PubMed Web of Science ®Google Scholar
• Aw F, Goyer I, Raboisson MJ, Boutin C, Major P, Dahdah N. Accelerated cardiac rhabdomyoma regression with everolimus in infants with tuberous sclerosis complex. Pediatr Cardiol. 2017;38(2):394–400. doi:10.1007/s00246-016-1528-y27878332
   PubMed Web of Science ®Google Scholar
• Krueger DA, Capal JK, Curatolo P, et al. TSCure research group. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): multicentre clinical experience. Eur J Paediatr Neurol. 2018;22(6):1066–1073. doi:10.1016/j.ejpn.2018.06.00730005812
   PubMed Web of Science ®Google Scholar
• Samueli S, Dressler A, Gröppel G, Scholl T, Feucht M. Everolimus in infants with tuberous sclerosis complex-related West syndrome: first results from a single-center prospective observational study. Epilepsia. 2018;59(9):e142–e146. doi:10.1111/epi.1452930098008
   PubMed Web of Science ®Google Scholar
• Overwater IE, Verhaar BJ, Lingsma HF, et al. Interdependence of clinical factors predicting cognition in children with tuberous sclerosis complex. J Neurol. 2017;264(1):161–167. doi:10.1007/s00415-016-8335-527878438
   PubMed Web of Science ®Google Scholar
• Jóźwiak S, Kotulska K, Domańiska-Pakiela D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol. 2011;15:424–431. doi:10.1016/j.ejpn.2011.03.01021507691
   PubMed Web of Science ®Google Scholar
• Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol. 2010;14(2):146–149. doi:10.1016/j.ejpn.2009.03.00319369101
   PubMed Web of Science ®Google Scholar
• van Eeghen AM, Pulsifer MB, Merker VL, et al. Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach. Dev Med Child Neurol. 2013;55(2):146–153. doi:10.1111/dmcn.1204423205844
   PubMed Web of Science ®Google Scholar
• Krueger DA, Sadhwani A, Byars AW, et al. Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders. Ann Clin Transl Neurol. 2017;4(12):877–887. doi:10.1002/acn3.49429296616
   PubMed Web of Science ®Google Scholar
• Thien A, Prentzell MT, Holzwarth B, et al. TSC1 activates TGF-β-Smad2/3 signaling in growth arrest and epithelial-to-mesenchymal transition. Dev Cell. 2015;32(5):617–630. doi:10.1016/j.devcel.2015.01.02625727005
   PubMed Web of Science ®Google Scholar